Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Lanreotide Demonstrates Confirmed Efficacy in Advanced Bronchopulmonary NETs

November 11th 2021

Lanreotide autogel/depot administered at 120 mg every 28 days may be an appropriate treatment for patients with advanced bronchopulmonary neuroendocrine tumors.

Saif Shares Insights on Single-Agent PARP Inhibitors and Combination Therapies for Pancreatic Cancer

November 10th 2021

Wasif M. Saif, MD, discusses the evolving role of PARP inhibitors and anticipated trends for research in pancreatic cancer.

Dr. Saif on the Rationale to Utilize PARP Inhibitors in BRCA+ Pancreatic Cancer

November 10th 2021

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

PEN-221 Demonstrates Clinical Benefit in Gastrointestinal NETs

November 10th 2021

The small molecule drug conjugate PEN-221 was generally well tolerated and elicited significant clinical benefit in patients with pretreated gastrointestinal neuroendocrine tumors.

Role of TACE and TARE in the Treatment of HCC

November 10th 2021

Andrea Casadei Gardini, MD, and Stephen L. Chan, MD, examine the use of TACE and TARE-Y90 for the treatment of HCC.

Updates to Adjuvant and Neoadjuvant Therapy in Early HCC

November 10th 2021

Stephen L. Chan, MD, reviews the case of a 72-year-old woman with mild alcoholic cirrhosis and provides insight on the potential role of adjuvant and neoadjuvant therapy for the treatment of HCC.

Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular Carcinoma

November 10th 2021

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.

DF1001 Gets Orphan Drug Designation From FDA for Esophageal Cancer

November 9th 2021

The FDA has granted an orphan drug designation to the HER2-targeted natural killer cell engager therapy, DF1001, as a potential therapeutic option for patients with esophageal cancer.

Dr. Mukherjee on Determining When to Initiate Immunotherapy in Gastroesophageal Cancer

November 9th 2021

Sarbajit Mukherjee, MD, MS, discusses considerations to inform when to initiate immunotherapy in gastroesophageal cancer.

Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma, as Efforts Shift to Target Other FGFR Alterations

November 9th 2021

Sameek Roychowdhury, MD, PhD, discusses the efficacy and safety data reported with infigratinib in FGFR2-positive cholangiocarcinoma, nuances to treatment with the agent, and ongoing research efforts to further improve outcomes in this population.

2021 ISGIO Meeting Packed With Multidisciplinary Updates in Gastrointestinal Cancers

November 9th 2021

Gastrointestinal cancer is increasingly viewed through a multidisciplinary lens, and the 2021 International Society of Gastrointestinal Oncology Annual Meeting produced intriguing developments in the armamentarium.

Dr. Marshall on the Potential Utility of Trastuzumab Deruxtecan in HER2+ Gastric Cancer

November 8th 2021

John L. Marshall, MD, discusses the potential utility of trastuzumab deruxtecan in HER2-positive gastric cancer.

Yarchoan Talks Research Directions in Fibrolamellar Carcinoma

November 4th 2021

Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to expand the limited paradigm in this disease.

Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma

November 1st 2021

The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.

Pancreatic Cancer Incidence Rises, Notably Among Younger Women

October 31st 2021

Incidence of pancreatic cancer incidence rose overall from 2000 to 2018, with a significant increase in women younger than 55 years, especially those aged 15 to 35 years.

Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases

October 28th 2021

Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factors to consider during surgical and systemic treatment decisions, and the importance of multidisciplinary care in this patient population.

Dr. Ku on Evaluating Zanidatamab Plus Chemotherapy in HER2-Expressing GEA

October 27th 2021

Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Dr. Shroff on Unmet Needs in Advanced Biliary Tract Cancer

October 26th 2021

Rachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.

Dr. Catenacci on Navigating HER2 Testing in Gastric/GEJ Cancer

October 25th 2021

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Dr. Heimbach on the Need for Multidisciplinary Care in HCC

October 25th 2021

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.